Literature DB >> 8348508

The appearance of Kaposi sarcoma during corticosteroid therapy.

A Trattner1, E Hodak, M David, M Sandbank.   

Abstract

BACKGROUND: Four epidemiologic types of Kaposi sarcoma (KS) are known: classic KS, endemic African KS, epidemic or acquired immunodeficiency syndrome-related KS, and KS associated with immunosuppressive therapy. In most of the latter patients, KS was reported to have developed after organ transplantation, particularly renal transplantation. Thirty-nine patients who have not had a transplant have been reported to have KS associated with corticosteroid therapy.
METHODS: The authors studied 10 patients with the appearance of KS during corticosteroid therapy (6 men, 4 women; age range, 42-79 years) who were treated with corticosteroids for autoimmune disorders (5 patients), lymphoproliferative disorders (2 patients), and diseases unrelated to the immune system (3 patients).
RESULTS: Genetically programmed susceptibility to corticosteroid-related KS was suggested by the descent of the study patients as well as most of those reported previously. The prognosis was guarded in all the study patients.
CONCLUSIONS: Corticosteroids should be withdrawn to achieve clinical remission.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348508     DOI: 10.1002/1097-0142(19930901)72:5<1779::aid-cncr2820720543>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  HHV-8 positive, HIV negative disseminated Kaposi's sarcoma complicating steroid dependent ulcerative colitis: a successfully treated case.

Authors:  A Bursics; K Morvay; K Abrahám; M Marschalkó; M Kardos; B Járay; K Nagy
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 2.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  Oral candidiasis, HIV, and saliva glucocorticoids.

Authors:  C O Enwonwu; V I Meeks
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

4.  Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma.

Authors:  G Flamini; S Magalini; G Curigliano; G Nanni; A Boninsegna; S Agnes; D Faticato; M Castagneto; A Cittadini
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  A review of the use of blood and blood products in HIV-infected patients.

Authors:  Karin van den Berg; James van Hasselt; Evan Bloch; Robert Crookes; James Kelley; Jonathan Berger; Charlotte Ingram; Anel Dippenaar; Rajendra Thejpal; Neil Littleton; Tersia Elliz; Gary Reubenson; Mark Cotton; Jennifer C Hull; Pamela Moodley; Yasmin Goga; William Eldridge; Moosa Patel; Eric Hefer; Arthur Bird
Journal:  South Afr J HIV Med       Date:  2012-06-07       Impact factor: 2.744

6.  Kaposi sarcoma after corticosteroid therapy for idiopathic thrombocytopenic purpura.

Authors:  Kwang Hyun Choi; Jae Ho Byun; Jun Young Lee; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

7.  Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Authors:  Natalie Galanina; Aaron M Goodman; Philip R Cohen; Garrett M Frampton; Razelle Kurzrock
Journal:  Cancer Immunol Res       Date:  2018-09-07       Impact factor: 11.151

Review 8.  Diagnosis and Treatment of Kaposi Sarcoma.

Authors:  Johann W Schneider; Dirk P Dittmer
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

9.  Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8.

Authors:  A V Moses; K N Fish; R Ruhl; P P Smith; J G Strussenberg; L Zhu; B Chandran; J A Nelson
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.

Authors:  Zhiqiang Qin; Lu Dai; Michael Defee; Victoria J Findlay; Dennis K Watson; Bryan P Toole; Jennifer Cameron; Francesca Peruzzi; Keith Kirkwood; Chris Parsons
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.